AIDS foundation lobbying Merck on price; Lupin gets FDA nod for generic Topamax; and much more

> In a series of ads, the AIDS Healthcare Foundation is urging Merck to change its pricing and access policies, criticizing an increase of up to six times the price of its anti-HIV drug Stocrin in Mexico than in other Latin American countries. Report

> India's Lupin said it has received tentative FDA approval for its Topiramate tablets, a generic version of the Ortho-McNeil seizure medication Topamax. Report

> AstraZeneca is asking the FDA to broaden the use of injectable Nexium for use in patients with peptic ulcer bleeding following therapeutic endoscopy. Release

> Pharmacopeia said it will cut its workforce by about 15 percent and expects to reduce its annual operating expenditures by at least $10 million in 2009. Report

> India's Dabur Pharma reported a fourfold surge in net profits on robust growth in its oncology business. Report

> Zydus Cadila announced its foray into Spain, the fifth largest pharmaceutical market, through the acquisition of Laboratories Combix for an undisclosed amount. Report

> Bristol-Myers Squibb is adding two oncology drugs to its pipeline with the acquisition of Kosan Biosciences. Report

> An expert panel was underwhelmed by GlaxoSmithKline's data for Promacta, a treatment designed to decrease the frequency and severity of bleeding episodes in people with thrombocytopenic purpura. Report

> New Jersey-based Alfacell took a major hit as it announced that its drug Onconase missed the primary endpoint in a Phase III study. Report

 > San Diego's Favrille is making massive cuts following the trial failure of Specifid announced earlier this week. Layoff report

And Finally... Solving the mystery of why type 1 diabetes is so prevalent in Finland could be the key to teasing out the causes of the disease. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.